The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of olaparib, temozolomide, and pembrolizumab in a phase 2 trial in patients with progressive glioblastoma.
 
Luis Gonzalez Castro
Employment - Takeda (I); Teladoc
Stock and Other Ownership Interests - Takeda (I)
Consulting or Advisory Role - BMJ publishing; Elsevier; Oakstone Publishing
Research Funding - Merck (Inst)
 
Christine Sceppa
No Relationships to Disclose
 
Catharina Westergaard
No Relationships to Disclose
 
Rachel Fox
No Relationships to Disclose
 
Ugonma Chukwueke
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I); Becton Dickinson (I); Danaher (I); Johnson and Johnson (I); Medtronic (I); Novartis (I)
 
Gilbert Youssef
Employment - Dana Farber Cancer Hospital; Takeda (I)
 
Elisa Aquilanti
No Relationships to Disclose
 
Eudocia Lee
Consulting or Advisory Role - Global Coalition for Adaptive Research
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
David Reardon
Stock and Other Ownership Interests - Anheart Therapeutics; Bionaut Labs
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Avita Biomedical, Inc.; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCaVa; Chimeric Therapeutics; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; Monteris Medical; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Avita Biomedical; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCava; Chimeric Therapeutics; Deciphera; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Asvattha Therapeutics (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); InSightec (Inst); Merck (Inst); NeoTX (Inst); Novartis (Inst); Omniox
 
Omar Arnaout
No Relationships to Disclose
 
Wenya Linda Bi
No Relationships to Disclose
 
Pierpaolo Peruzzi
No Relationships to Disclose
 
Alexandra Golby
Stock and Other Ownership Interests - Merck
 
Jiyoon Kim
No Relationships to Disclose
 
Rafael Vega
No Relationships to Disclose
 
Lauren Schaff
Honoraria - Resonance
Consulting or Advisory Role - BTG; Ono Pharmaceutical; SERVIER
Research Funding - BTG (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent for use of low-dose glucarpidase to clear systemic MTX
 
Isabel Arrillaga
Consulting or Advisory Role - Boehringer Ingelheim; Forma Therapeutics
Research Funding - Astex Pharmaceuticals; GlaxoSmithKline
 
Keith Ligon
Stock and Other Ownership Interests - Travera
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER; Travera
 
Robert Prins
No Relationships to Disclose
 
Patrick Wen
Consulting or Advisory Role - Alexion Pharmaceuticals; Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Bristol Myers Squibb Foundation; Celularity; Chimerix; Day One Biopharmaceuticals; Fore Biotherapeutics; Genenta Science; GlaxoSmithKline; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novocure; Novocure; Nuvation Bio; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Bristol-Myers Squibb/Medarex (Inst); Chimerix (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Global Coalition for Adaptive Research (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Philogen (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)